TY - JOUR
T1 - Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide
T2 - SUSTAIN 7 post hoc analyses
AU - Pratley, Richard E.
AU - Aroda, Vanita R.
AU - Catarig, Andrei Mircea
AU - Lingvay, Ildiko
AU - Ludemann, Jorg
AU - Yildirim, Emre
AU - Viljoen, Adie
N1 - Funding Information:
This work was supported by Novo Nordisk A/S. Editorial support was provided by Stacy Carl-McGrath PhD (AXON Communications), funded by Novo Nordisk A/S.
Publisher Copyright:
©
PY - 2020/11/16
Y1 - 2020/11/16
N2 - Objective In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA 1c) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide. Design Analyses by baseline age (<65, ≥65 years), sex (male, female), diabetes duration (≤5, >5-10, >10 years), HbA 1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (<30, 30-<35, ≥35 kg/m 2). Setting 194 sites; 16 countries. Participants Subjects with T2D (n=1199) exposed to treatment. Interventions Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly. Primary and secondary outcome measures Change in HbA 1c (primary endpoint) and BW (confirmatory secondary endpoint) from baseline to week 40; proportion of subjects achieving HbA 1c targets (<7%, ≤6.5% (<53, ≤48 mmol/mol)) and weight-loss responses (≥5%, ≥10%) at week 40; and safety. Results HbA 1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA 1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus dulaglutide within each subgroup category and, excepting glycaemic control within the low-dose comparison in HbA 1c subgroups, this was irrespective of subgroup or dose comparison. Gastrointestinal adverse events, the most common with both treatments, were reported by more women than men and, with semaglutide, decreased with increasing BMI. Conclusions Consistently greater improvements in HbA 1c and BW with semaglutide versus dulaglutide, regardless of age, sex, diabetes duration, glycaemic control and BMI, support the efficacy of semaglutide across the continuum of care in a heterogeneous population with T2D. Trial registration number NCT02648204.
AB - Objective In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA 1c) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide. Design Analyses by baseline age (<65, ≥65 years), sex (male, female), diabetes duration (≤5, >5-10, >10 years), HbA 1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (<30, 30-<35, ≥35 kg/m 2). Setting 194 sites; 16 countries. Participants Subjects with T2D (n=1199) exposed to treatment. Interventions Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly. Primary and secondary outcome measures Change in HbA 1c (primary endpoint) and BW (confirmatory secondary endpoint) from baseline to week 40; proportion of subjects achieving HbA 1c targets (<7%, ≤6.5% (<53, ≤48 mmol/mol)) and weight-loss responses (≥5%, ≥10%) at week 40; and safety. Results HbA 1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA 1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus dulaglutide within each subgroup category and, excepting glycaemic control within the low-dose comparison in HbA 1c subgroups, this was irrespective of subgroup or dose comparison. Gastrointestinal adverse events, the most common with both treatments, were reported by more women than men and, with semaglutide, decreased with increasing BMI. Conclusions Consistently greater improvements in HbA 1c and BW with semaglutide versus dulaglutide, regardless of age, sex, diabetes duration, glycaemic control and BMI, support the efficacy of semaglutide across the continuum of care in a heterogeneous population with T2D. Trial registration number NCT02648204.
KW - clinical trials
KW - diabetes & endocrinology
KW - general diabetes
UR - http://www.scopus.com/inward/record.url?scp=85096271011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096271011&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-037883
DO - 10.1136/bmjopen-2020-037883
M3 - Article
C2 - 33199417
AN - SCOPUS:85096271011
SN - 2044-6055
VL - 10
JO - BMJ Open
JF - BMJ Open
IS - 11
M1 - 037883
ER -